National Research (NASDAQ:NRC) Reaches New 52-Week Low at $33.01

National Research Co. (NASDAQ:NRC)’s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $33.01 and last traded at $33.01, with a volume of 1052 shares changing hands. The stock had previously closed at $33.32.

Analysts Set New Price Targets

Separately, TheStreet lowered shares of National Research from a “b-” rating to a “c+” rating in a research note on Thursday, January 11th.

National Research Stock Up 3.5 %

The business’s 50 day moving average is $38.57 and its 200-day moving average is $40.13. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.67 and a current ratio of 0.67. The firm has a market capitalization of $811.62 million, a price-to-earnings ratio of 27.22 and a beta of 0.42.

National Research (NASDAQ:NRC) last posted its earnings results on Tuesday, February 13th. The company reported $0.36 earnings per share (EPS) for the quarter. National Research had a net margin of 20.84% and a return on equity of 47.79%. The business had revenue of $38.00 million for the quarter.

National Research Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 29th were issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date of this dividend was Wednesday, March 27th. National Research’s dividend payout ratio (DPR) is presently 38.40%.

Institutional Trading of National Research

A number of hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its holdings in National Research by 2.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,656 shares of the company’s stock valued at $360,000 after purchasing an additional 231 shares during the period. Rhumbline Advisers lifted its holdings in shares of National Research by 1.4% during the 2nd quarter. Rhumbline Advisers now owns 19,331 shares of the company’s stock worth $841,000 after acquiring an additional 272 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of National Research by 4.2% during the 4th quarter. MetLife Investment Management LLC now owns 7,239 shares of the company’s stock worth $270,000 after acquiring an additional 292 shares during the period. Legal & General Group Plc lifted its holdings in shares of National Research by 2.3% during the 4th quarter. Legal & General Group Plc now owns 13,522 shares of the company’s stock worth $535,000 after acquiring an additional 306 shares during the period. Finally, Summit Global Investments lifted its holdings in shares of National Research by 3.8% during the 3rd quarter. Summit Global Investments now owns 8,452 shares of the company’s stock worth $375,000 after acquiring an additional 310 shares during the period. 47.26% of the stock is owned by institutional investors.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.